Comfort can be initiated according to the oncology immunotherapy patient relief project

Recently, the Beijing Kang League Charitable Foundation, together with Xinda Bio, launched the "Shuxin-Oncology Immunotherapy Patient Relief Project", which was launched on January 1, 2021 and is scheduled to be carried out simultaneously in project pharmacies in 190 cities across the country. The project aims to provide drug assistance to patients in urgent need of cancer immunotherapy drugs in China, and effectively reduce the financial burden on patients and families.
According to the National Cancer Center in 2019 released national cancer statistics show that the incidence of malignant tumors to maintain an annual increase of about 3.9%, mortality rate to maintain an annual increase of 2.5%, and continuously improve the overall cancer survival rate is a clinical goal.
to China's high morbidity and mortality rate of lung cancer as an example, the emergence of innovative treatment methods such as immunotherapy, extending the survival of patients, the future will also improve the overall survival rate of cancer patients to a certain extent. Among them, PD-1/PD-L1 inhibitors have achieved some effect on improving the survival rate of advanced cancer.
the project relief drug Xindili single anti-injection by Xinda Bio to the Beijing Kangmen Charitable Foundation donated free of charge. Chinese mainland Patients who have not progressed in the disease after using the drug on their own, after the project doctor assessed that the conditions of the drug can continue to be used, but because of the disease can not afford the full cost of treatment patients, according to their own claims, can voluntarily launch a request for help in the "comfort can rely on" project platform, the whole of 2021 patients can accept applications for help.
。